Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 21 Researches
7.4
USERS' SCORE
Good
Based on 2 Reviews
8.3
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%*
Total omega-3 fatty acids
346 mg
†
Docosahexaenoic acid (DHA)
250 mg
†
Eicosapentaenoic acid (EPA)
57 mg
†
Top Medical Research Studies
9
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
8
We explored the impact of omega-3 fatty acid supplementation, particularly docosahexaenoic acid (DHA), on cardiovascular health through the Vitamin D and Omega-3 Trial (VITAL). This comprehensive study included nearly 26,000 older adults from the U.S., who received a daily dose of 840 mg of omega-3 fatty acids.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
Read More
7
Marine n-3 PUFAs and cardiovascular risk
We set out to explore how levels of marine n-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), relate to cardiovascular (CV) events and overall mortality, specifically in patients receiving hemodialysis. This prospective study tracked 336 patients over five years, monitoring their CV health and vital statistics.
Our findings revealed a significant connection: patients with lower levels of these essential fatty acids had a heightened risk of experiencing CV events and higher all-cause mortality. We found that those in the lower tertile of n-3 PUFA levels (below 5.06 weight percent) faced notably worse outcomes. Interestingly, those with moderate to high n-3 PUFA levels enjoyed a reduced risk of CV complications and even all-cause mortality, which indicates that increasing levels of EPA and DHA might be beneficial.
These insights suggest that maintaining healthy levels of marine n-3 PUFAs could be crucial for patients undergoing hemodialysis. We observed a potential threshold effect, indicating that risks of CV issues climb for those with n-3 PUFA levels below a certain point. This reinforces the importance of dietary omega-3 fatty acids for heart health, especially in vulnerable populations.
Our findings revealed a significant connection: patients with lower levels of these essential fatty acids had a heightened risk of experiencing CV events and higher all-cause mortality. We found that those in the lower tertile of n-3 PUFA levels (below 5.06 weight percent) faced notably worse outcomes. Interestingly, those with moderate to high n-3 PUFA levels enjoyed a reduced risk of CV complications and even all-cause mortality, which indicates that increasing levels of EPA and DHA might be beneficial.
These insights suggest that maintaining healthy levels of marine n-3 PUFAs could be crucial for patients undergoing hemodialysis. We observed a potential threshold effect, indicating that risks of CV issues climb for those with n-3 PUFA levels below a certain point. This reinforces the importance of dietary omega-3 fatty acids for heart health, especially in vulnerable populations.
Read More
Most Useful Reviews
7.5
Supports cardiovascular health
Every mum desires the best for her baby. Our DHA Omega-3 Prenatal Complex features DHA, an essential nutrient for a healthy pregnancy. DHA also aids in the development of your baby's brain and nervous system. Just one capsule daily suffices.
Read More
7.5
Promotes cardiovascular health
Just one soft gel a day can promote my baby's brain and eye health while supporting my cardiovascular health.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 21 Researches
7.4
- All Researches
9
We conducted a network meta-analysis to investigate the effects of docosahexaenoic acid, an omega-3 fatty acid, on heart failure management. By examining various randomized controlled trials, we aimed to understand how different dosages and durations of supplementation impact heart function.
Our findings revealed that high-dose supplementation—ranging from 2000 to 4000 mg per day—over more than one year significantly improved heart function, particularly left ventricular ejection fraction and peak oxygen consumption. This indicates a promising role for docosahexaenoic acid in enhancing cardiovascular health in patients dealing with heart failure.
However, we also noted that lower doses and shorter treatment periods did not yield the same benefits. Importantly, the analysis showed no significant increase in dropout rates or all-cause mortality associated with omega-3 supplementation when compared to control groups.
Overall, the evidence suggests that long-term, high-dose docosahexaenoic acid supplementation can positively influence heart function without heightened risk. Future research should focus on more rigorous trials to further validate these findings and address any biases.
Our findings revealed that high-dose supplementation—ranging from 2000 to 4000 mg per day—over more than one year significantly improved heart function, particularly left ventricular ejection fraction and peak oxygen consumption. This indicates a promising role for docosahexaenoic acid in enhancing cardiovascular health in patients dealing with heart failure.
However, we also noted that lower doses and shorter treatment periods did not yield the same benefits. Importantly, the analysis showed no significant increase in dropout rates or all-cause mortality associated with omega-3 supplementation when compared to control groups.
Overall, the evidence suggests that long-term, high-dose docosahexaenoic acid supplementation can positively influence heart function without heightened risk. Future research should focus on more rigorous trials to further validate these findings and address any biases.
Read More
9
Icosapent ethyl reduces cardiovascular risks
We explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing cardiovascular events among statin-treated patients who had high cardiovascular risk and controlled cholesterol levels.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
Read More
9
We delved into how Antarctic krill oil, rich in eicosapentaenoic acid (EPA), can influence cardiovascular health, specifically in the context of obesity. Our focus centered on its effects in mice fed a high-fat diet, which typically leads to increased cholesterol levels and oxidative stress—conditions that can heighten cardiovascular disease risk.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Read More
9
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
8
We explored the impact of omega-3 fatty acid supplementation, particularly docosahexaenoic acid (DHA), on cardiovascular health through the Vitamin D and Omega-3 Trial (VITAL). This comprehensive study included nearly 26,000 older adults from the U.S., who received a daily dose of 840 mg of omega-3 fatty acids.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Supports cardiovascular health
Every mum desires the best for her baby. Our DHA Omega-3 Prenatal Complex features DHA, an essential nutrient for a healthy pregnancy. DHA also aids in the development of your baby's brain and nervous system. Just one capsule daily suffices.
Read More
7.5
Promotes cardiovascular health
Just one soft gel a day can promote my baby's brain and eye health while supporting my cardiovascular health.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. doi:10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. doi:10.3390/jcdd12020060
- Ren Y, Chen B, Zhang H, Xu S. A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults. Geroscience. 2025. doi:10.1007/s11357-025-01544-6
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
- Arghavani H, Bilodeau JF, Rudkowska I. Association Between Circulating Fatty Acids and Blood Pressure: A Review. Curr Nutr Rep. 2025;14:15. doi:10.1007/s13668-024-00602-3
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. doi:10.1039/d4fo04961f
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. doi:10.1016/j.prostaglandins.2025.106948
- Berkowitz L, Echeverría G, Salazar C, Faúndez C, Coe CL, et al. Lipidomic Signature of Healthy Diet Adherence and Its Association with Cardiometabolic Risk in American Adults. Nutrients. 2024;16. doi:10.3390/nu16233995
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. doi:10.1016/j.plefa.2024.102655
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. doi:10.1093/eurjpc/zwae315
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. doi:10.3390/ijms251810136
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. doi:10.1007/s40261-024-01417-4
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. doi:10.7759/cureus.73417
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. doi:10.3390/nu16213614
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
- Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, et al. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes. Atheroscler Plus. 2024;58:1. doi:10.1016/j.athplu.2024.09.002
